TopoTarget A/S is a Denmark-based biotech company that focuses on treatments for cancer patients and other cancer-related disorders. Its activities cover various aspects of drug development, including assay development, screening, biology, medicinal chemistry, preclinical and clinical trials, regulatory affairs, business development and marketing and sales. TopoTarget’s main product is Savene/Totect, which is used for the prevention of tissue damage caused by extravasation accidents with chemotherapy. Its clinical pipeline has six drug candidates, namely Belinostat (PXD 101), APO866, Zemba, APO010, HSP90 and mTOR. Its therapeutic areas are divided into two segments: Cancer and Non Cancer. The Cancer division focuses on Extravasation, Solid Tumors and Haematology, Basal Cell Carcinoma, Familial Adenomatous Polyposis and HER2+ Cancers. The Non Cancer therapeutic division focuses on Acen, X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) and Gout.